GU Cancers 2023 | COSMIC-313: cabo + nivo + ipi in 1L advanced RCC of IMDC intermediate or poor risk

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, shares the results of the Phase III COSMIC-313 (NCT03937219) trial of cabozantinib (cabo) in combination with nivolumab (nivo) and ipilimumab (ipi) in previously untreated advanced renal cell carcinoma (aRCC) of international metastatic renal cell carcinoma database consortium (IMDC) intermediate or poor risk. The primary endpoint was progression-free survival (PFS) and the secondary endpoint was overall survival (OS) objective response rate (ORR) and safety were additional endpoints. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.